(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Biden Administration’s announcement to curb drug manufacturer patent abuses. “We applaud the Biden Administration for taking real action to reduce prescription
PBMs Support and Encourage Biosimilar Competition Increased biosimilar competition drives down prescription drug costs Having multiple biosimilar and reference biologic competitor products with equivalent patient benefits on the market allows pharmacy benefit companies, PBMs, to push manufacturers to compete on
Pharmacy Direct and Indirect Remuneration (DIR) Value-based Pharmacy Reimbursement Reduces Drug Costs for Medicare Beneficiaries, Lowers Spending. Pharmacy direct and indirect remuneration, or Pharmacy DIR, is a form of value-based contracting in Medicare Part D. Pharmacy DIR increases the quality
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new report, “Drug Manufacturer Strategies for Keeping Drug Costs High,” on pharmaceutical industry pricing tactics that increase prescription drug costs for patients. The report, conducted by the research firm Visante,
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the “2021 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds:” “The
(Washington, D.C.) — The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administration’s 100-day review of the actions needed to address vulnerabilities in our nation’s pharmaceutical supply chain and what measures need to be taken in order
May is Asthma Awareness Month, and today – May 5 – is World Asthma Day. The Asthma and Allergy Foundation of America is marking the day with the release of their 2021 Asthma Capitals Report.
(Washington, D.C.) — The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administration’s February 24, 2021, Executive Order on America’s Supply Chains. “As representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter
The Medicare Prescription Drug Rebate Rule The Medicare Part D prescription drug benefit provides our nation’s seniors with affordable drug coverage, which is more important now than ever. The rebate rule clumsily attempts to eliminate the primary tool used by
(Washington, D.C.) — Pharmaceutical Care Management Association President and CEO JC Scott issued the following statement on legislation passed by Congress to increase access to biosimilars, “The Ensuring Innovation Act” and the “Advancing Education on Biosimilars Act of 2021.” “We applaud Congress for
©2024 PCMA. All Rights Reserved.
